U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07611305) titled 'ProGo Menopause Wellbeing Study' on May 21.
Brief Summary: This study will evaluate whether ProGo(R), a salmon protein hydrolysate (SPH), helps to moderate BMI and improve quality of life (QoL) in menopausal women. Healthy, overweight (BMI 25-32.5) menopausal women aged 40-65 years with will be enrolled and participants will be randomized to receive ProGo(R) (2.0 g), ProGo(R) (4.0 g), or placebo (in a 2:2:1 ratio) once daily for 18 weeks.
ProGo(R) peptides have demonstrated moderate weight loss of 6%-7% in prior human studies likely a result of improved energy levels and reduced inflammation with improved metabolic health.
This stu...